Articles tagged with Parkinsons Disease
A study found that NLX-112 reduced dyskinesia and improved movement symptoms in marmosets with Parkinson's-like symptoms. The results suggest that the drug has potential as a future treatment for people with Parkinson's, offering hope for those affected by debilitating movement problems.
Researchers used gene-editing tools to introduce the Parkinson's mutation into marmoset monkey stem cells, creating a primate model for studying disease progression and testing therapies. The edited cells exhibited characteristics of Parkinson's, such as abnormal cellular chemistry and reduced connections with neighboring neurons.
People with mild to moderate Parkinson's disease showed significant improvements in speech, handwriting, and motor skills after playing pingpong once a week for six months. The study found that participants experienced reductions in symptoms such as tremors, rigidity, and balance problems.
A new study by UCL researchers has found a link between iron accumulation in the brain and cognitive decline in people with Parkinson's disease. The study used advanced MRI techniques to detect iron deposits in different brain regions, revealing associations with poor memory and thinking scores.
Researchers have successfully solved the structure of Parkinson's disease-related protein LRRK2 inside cells using a pioneering technique. The study reveals that pathogenic LRRK2 forms exquisitely-organized double-helices around microtubules, suggesting a potential target for therapies.
Researchers have discovered a promising molecule, BT13, that may slow or stop Parkinson's disease. By increasing dopamine levels and protecting brain cells, BT13 has shown promise in treating the condition.
Researchers at Trinity College Dublin have discovered that the overactive LRRK2 enzyme wreaks havoc on motor and cognitive abilities in Parkinson's disease. The team has simulated the activity of the enzyme in the laboratory, visualizing its effects on protein complexes and paving the way for new treatments.
A long-term study of 200,000 long-distance skiers found they were almost 30% less likely to develop Parkinson's disease. This 'motor reserve' dissipates with time and age.
A randomized clinical trial found that outpatient palliative care was associated with better patient and caregiver outcomes for patients with Parkinson disease. The study included 210 patients and 175 caregivers and examined the effects of palliative care on quality of life, mood, and sleep.
Researchers have developed a technology that can distinguish between Parkinson's disease and multiple system atrophy with high accuracy. The Protein Misfolding Cyclic Amplification (PMCA) test targets misfolded alpha-synuclein aggregates, allowing doctors to identify the correct disease and pursue timely treatment.
Researchers found that people with Parkinson's carrying APOE4 variant experience faster cognitive decline and more severe dementia. Targeting APOE may reduce dementia risk in Parkinson's patients.
A Danish registry study found a significant association between neurological disorders, including dementia and Parkinson's disease, and increased risk of suicide. The study analyzed nearly 40 years of data for 7.3 million people, revealing that those with neurological conditions were more likely to die by suicide.
A recent study by KU Leuven researchers has discovered a link between a defective ATP13A2 gene and cell death in Parkinson's disease. The study found that the gene plays a crucial role in transporting polyamines, essential molecules supporting various cellular functions.
The Parkinson's Foundation has awarded a total of $30,000 to three physical therapists through its new Physical Therapy Faculty Award. The award will support individual project initiatives aimed at improving life for people with Parkinson's disease, including developing academic partnerships and heart rate monitoring protocols.
A collaboration between Rutgers University and Scripps Research has led to the discovery of a small molecule that reduces α-synuclein protein levels, potentially slowing or stopping Parkinson's disease progression. This finding offers hope for early-stage patients and may be applicable to other neurodegenerative diseases like Alzheimer's.
Researchers at Cedars-Sinai Medical Center found that people with Parkinson's disease before age 50 were born with disordered brain cells. The study suggests a potential new treatment using PEP005, which reduced alpha-synuclein levels and countered abnormal enzyme activity in dopamine neurons.
A study published in Environmental Health found a link between air pollution from traffic and an increased risk of developing dementia, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Living near green spaces appears to have protective effects against these neurological disorders.
Researchers at Cold Spring Harbor Laboratory have developed a chemical compound, UBP1700, that inhibits certain NMDARs while allowing others to function. This allows for the precise investigation of NMDAR activity in both healthy and diseased brains.
Scientists have discovered a non-invasive technique that can successfully target both cholinergic and dopaminergic neurons, two major neurotransmitter systems affected by Parkinson's disease. This breakthrough could lead to a more precise and effective treatment for the condition.
A study led by University at Buffalo biologist Shermali Gunawardena has explored the properties of alpha-synuclein, a protein associated with Parkinson's disease. The research suggests that deleting a specific region of the protein may help prevent key problems that occur when too much alpha-synuclein is produced.
Researchers have identified a probiotic that slows and reverses the build-up of alpha-synuclein protein, which is associated with Parkinson's disease. The probiotic, Bacillus subtilis, produces chemicals that change how enzymes process specific fats, preventing toxic clumps from forming.
A UK-wide trial has started recruiting patients for a three-year study on preventing falls in people with Parkinson's disease, led by the Royal United Hospitals Bath NHS Foundation Trust and the University of Bristol. The trial will test whether a commonly prescribed dementia drug can prevent debilitating falls and improve patients' qu...
Researchers propose a new computational analysis method that uses keystroke time series data to detect early stages of Parkinson's disease. The method, based on fuzzy recurrence plots, is less physically demanding than traditional testing methods and shows encouraging results.
Researchers discover a potential treatment for Parkinson's disease dyskinesias, a devastating side effect of long-term treatment. HU-308 reduces involuntary movements and improves symptoms in mice, offering a safer alternative to medicinal cannabis.
Researchers found that a weekly multi-modal regime combining physical and cognitive exercises significantly improved motor and non-motor symptoms in Parkinson's patients. The study suggests tailored exercise programs could improve quality of life for those affected by the disease.
A recent clinical trial found that nilotinib increases dopamine levels and reduces neurotoxic proteins in people with Parkinson's disease. The study also showed potential in halting motor and non-motor decline, making it a promising treatment option.
The Defitech Foundation has teamed up with EPFL, CHUV and UNIL to develop innovative therapies for paraplegic and quadriplegic patients. Researchers will trial personalized treatments that use electrical stimulation to restore motor function.
A clinical trial found nilotinib to be safe and tolerable for patients with moderate to advanced Parkinson's disease, but did not show a clinically meaningful benefit. The study, led by Northwestern University, involved 76 participants and tested three doses of the medication over six months.
Chaperone proteins protect α-Synuclein from cell damage in healthy cells. Impaired chaperone binding leads to α-Synuclein accumulation and mitochondrial destruction, characteristic of Parkinson's disease. The study provides new insights into the role of molecular bodyguards in neurodegenerative disorders.
Researchers found structural diversity in alpha-synuclein protein deposits associated with Parkinson's and MSA, revealing potential starting points for medicines. The study suggests that the variability of Parkinson's disease could be related to differences in the folding of aggregated alpha-synuclein.
The 2019 Queen Elizabeth Prize for Engineering is awarded to four US engineers who created the first global satellite-based positioning system, GPS. The award celebrates the global benefit of engineering innovation on humanity.
Researchers identified nine cases of people who lost their ability to swim after receiving deep brain stimulation for Parkinson's disease. The study highlights the potential risk of drowning and emphasizes the need for supervised assessment before engaging in deep water activities.
A recent study by the University of Helsinki found a significant link between increased use of antibiotics and an elevated risk of developing Parkinson's disease. The study suggests that excessive antibiotic use can disrupt the gut microbial ecosystem, leading to pathological changes in the intestine years before typical symptoms appear.
Mount Sinai researchers used MGNA to identify key regulators of the Parkinson's molecular network, including STMN2. The study found that reduction of STMN2 led to upregulation of genes associated with the disease and disrupted motor function control in mice.
Patients with inflammatory bowel disease are more likely to develop Parkinson's disease due to shared underlying inflammation. While the risk is small, early detection and intervention may be crucial in slowing or stopping PD progression.
Researchers developed SleepFit, a new app to monitor Parkinson's disease, which showed good agreement between prospectively and retrospectively collected data. The study found that patients with higher disagreement tended to have more advanced disease or worse sleep quality.
A new mechanism has been discovered for the development of Parkinson's disease, which could lead to a more targeted therapy. Researchers have found that excessive calcium influx through specific ion channels, Cav2.3 channels, contribute significantly to the disease.
Researchers found that Parkinson's disease dopamine neurons can shut down without fully dying, releasing chemicals that cause inflammation and senescence in healthy neighbors. This discovery suggests new avenues for therapies targeting SATB1 or p21 to prevent or slow the disease.
A review of case-control fecal gut microbiome studies in Parkinson's disease found varying results, but replicated findings include an increase in Verrucomicrobiaceae and Akkermansia. The researchers recommend integrating existing data to address confounders and propose future studies focus on biomarkers for PD diagnosis.
A Dutch study found that early onset of PD, memory and thinking impairment, and high levodopa medication use are linked to increased mortality. The study suggests that progressive motor impairment may be a key factor in the association between PD and reduced life expectancy.
Scientists propose that Parkinson's disease can be divided into two subtypes, with some cases starting in the gut and others in the brain. This hypothesis reconciles discrepant findings from neuropathological literature, suggesting a more complex understanding of the disorder's origins.
Scientists at the University of Dundee have created a method to permanently attach a small sugar molecule called O-GlcNAc to proteins in human cells. This allows them to investigate its role in neurological diseases such as Alzheimer's and Parkinson's, which are thought to be linked to O-GlcNAc disruption.
Researchers have identified a new enzyme that inhibits the LRRK2 pathway, which is responsible for most genetic cases of Parkinson's disease. The discovery provides hope for developing new treatments and suggests that the enzyme could benefit all individuals, regardless of whether they have Parkinson's or not.
A new three-year project aims to test the impact of sleep, exercise and low levels of alcohol on the glymphatic system, a recently discovered pathway that removes waste products from the brain. The study may lead to treatments that can target an important cause of both Parkinson's and Alzheimer's.
Researchers developed a novel approach to track tremor severity in Parkinson's patients, combining wearable sensors with machine-learning algorithms. The method accurately measures total and resting tremors throughout the day, even during free body movements.
The US Army has awarded Northeast Ohio Medical University (NEOMED) a $954,566 grant to study the impact of exercise on Parkinson's disease. The research aims to determine whether exercise can prevent or delay symptoms and provide a non-invasive therapeutic strategy for patients.
Researchers found gene therapy potential in treating neurological disorders like Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. New therapeutic approaches reprogram glial cells into motor neurons and deliver antibodies to protect against toxins.
A new strategy to treat Parkinson's disease has been developed by amplifying healthy GCase enzymes, alleviating symptoms in both human brain cells and mouse models. This approach may be relevant for multiple forms of PD with reduced activity of wild-type GCase.
A systematic review and meta-analysis of seven studies with 4.3 million participants found a potential association between bipolar disorder and an increased likelihood of a subsequent Parkinson disease diagnosis. However, subgroup analyses suggest possible overestimation of the magnitude of the associations.
A pioneering clinical trial will assess the safety and efficacy of cannabidiol (CBD) in alleviating hallucinations and delusions associated with Parkinson's-related psychosis. The study aims to determine whether CBD can correct abnormal brain functioning and improve quality of life for affected individuals.
A new study found that military veterans with post-traumatic stress disorder (PTSD) are more likely to experience a rare sleep disorder called REM sleep behavior disorder (RBD), which is also linked to an increased risk of developing neurodegenerative conditions like Parkinson's disease. Researchers hope that identifying patients with ...
Scientists observed how alpha-synuclein protein variants change over time, identifying initial stages of protein aggregates linked to early onset familial cases. They also found evidence of which protein species are important for amyloid filament growth and distinct structures depending on the mutation.
A team of researchers at the University of Pennsylvania is developing a critical tool for imaging the brains of patients with Parkinson's disease. They plan to use a special type of PET scan to detect the disease early on and provide detailed information about its progression.
Experts recommend promoting a 'brain-healthy lifestyle' through public education campaigns, research programs, and healthcare system preparedness. This can help reduce the risk of developing neurodegenerative diseases by emphasizing that healthy habits are generally good for brain health.
Researchers from Aarhus University discovered that Parkinson's patients have an immune imbalance in their blood, affecting the regulation of immune cells and anti-inflammatory molecules. This finding advocates for immune modulation as a potential alternative treatment for the disease.
Researchers identified genetic variants related to Parkinson's disease symptom onset, which could enable delimiting research on new therapeutic targets. The study, led by Cristina Malagelada, used biocomputing techniques and analyzed statistical interactions to identify genetic associations.
Researchers at Stanford University School of Medicine discovered a molecular defect that could lead to an accurate, early diagnosis of Parkinson's disease. They also identified a compound that reverses this defect in cells from patients and prevents neuronal death in animal models.
A Canadian team found that the LRRK2 gene is associated with an increased risk of Parkinson's disease, Crohn's disease, and leprosy due to enhanced inflammation. The study suggests that treating excessive inflammation may lead to new treatments and prevention strategies for these diseases.
Researchers at Neuroscience 2019 announce new gene therapy research promising to prevent, treat, and reverse incurable neurological disorders. Successes in restoring lost functions in animal models of neurological diseases are discussed, as well as technique advancements that may improve future treatments.
Researchers have found that a drug used to treat enlarged prostate may slow the progression of Parkinson's disease. Using big data and bench science, they discovered that terazosin can block cell death by activating an enzyme called PGK1, which is critical for cellular energy production.